NYSEAMERICAN:ATNM

Actinium Pharmaceuticals (ATNM) Stock Forecast, Price & News

$6.26

0.00 (0.00%)

(As of 09/20/2023 ET)

Compare

Today's Range: $6.14
▼
$6.43
50-Day Range: $7.12
▼
$14.26
52-Week Range: $5.87
▼
$15.12

Volume: 162,459 shs
Average Volume: 284,573 shs
Market Capitalization: $169.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.32

Profile Analyst Ratings Chart Competitors Earnings Headlines Options Chain Short Interest Social Media

Actinium Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 352.4% Upside
$28.32 Price Target
Short Interest: Bearish
7.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.05) to ($1.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.32, Actinium Pharmaceuticals has a forecasted upside of 352.4% from its current price of $6.26.
Amount of Analyst Coverage
Actinium Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.63% of the outstanding shares of Actinium Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Actinium Pharmaceuticals has recently decreased by 2.37%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Actinium Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Actinium Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATNM.

2.2

News and Social Media Coverage

News Sentiment
Actinium Pharmaceuticals has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Actinium Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
13 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.
MarketBeat Follows
7 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Actinium Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 22.38% of the stock of Actinium Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($2.05) to ($1.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Actinium Pharmaceuticals is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Actinium Pharmaceuticals is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Actinium Pharmaceuticals has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

ATNM Price History

30 days | 90 days | 365 days | Advanced Chart

ATNM Stock News Headlines

September 15, 2023 | msn.com

Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?

September 14, 2023 | americanbankingnews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to Sell by StockNews.com

September 21, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 10, 2023 | msn.com

HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead

September 7, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Inovio Pharmaceuticals (INO)

September 7, 2023 | finance.yahoo.com

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

September 7, 2023 | msn.com

HSBC Initiates Coverage of Actinium Pharmaceuticals (ATNM) with Buy Recommendation

September 1, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)

September 21, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 31, 2023 | finance.yahoo.com

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

August 21, 2023 | finance.yahoo.com

Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress

August 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Plus Therapeutics (PSTV)

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Actinium Pharmaceuticals (ATNM) Buy Recommendation

July 24, 2023 | finance.yahoo.com

Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

June 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Cognition Therapeutics (CGTX)

June 26, 2023 | finance.yahoo.com

SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data

June 23, 2023 | finance.yahoo.com

Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting

June 16, 2023 | finance.yahoo.com

Actinium Pharma to Present at the Maxim Healthcare Virtual Conference

June 12, 2023 | finance.yahoo.com

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

June 7, 2023 | finance.yahoo.com

Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes

May 22, 2023 | finance.yahoo.com

Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers

May 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), Sutro Biopharma (STRO) and Karuna Therapeutics (KRTX)

May 13, 2023 | forbes.com

Catalyst Pharmaceuticals

May 11, 2023 | finance.yahoo.com

Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)

April 28, 2023 | finance.yahoo.com

Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress

April 27, 2023 | finance.yahoo.com

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

April 21, 2023 | benzinga.com

Actinium Pharmaceuticals Stock (AMEX:ATNM), Dividends

See More Headlines

Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Company Calendar

Last Earnings: 8/14/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:ATNM
Previous Symbol: AMEX:ATNM
CUSIP: N/A
CIK: N/A
Web: www.actiniumpharmaceuticals.com
Phone: (646) 677-3870
Fax: N/A
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $28.32
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $11.60
Forecasted Upside/Downside: +352.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,020,000.00
Net Margins: N/A
Pretax Margin: -102,975.55%
Return on Equity: -74.73%
Return on Assets: -42.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.44
Quick Ratio: 10.44

Sales & Book Value

Annual Sales: $1.03 million
Price / Sales: 164.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.61 per share
Price / Book: 2.40

Miscellaneous

Outstanding Shares: 27,000,000
Free Float: 25,999,000
Market Cap: $169.02 million
Optionable: Optionable
Beta: 0.38

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Sandesh C. Seth M.B.A. (Age 59)
M.S., MBA, Chairman & CEO
Comp: $1.15M

Mr. Steven O'Loughlin BS (Age 37)
CFO & Corp. Sec.
Comp: $585k

Dr. Paul Diamond Esq.
Ph.D., VP of Patent & Legal Counsel

Dr. David Gould
Sr. VP of Corp. Devel. & Corp. Affairs

Dr. Bernie Cunningham P.M.P.
Ph.D., Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management

Dr. Qing Liang
VP & Head of Radiation Sciences

Dr. Avinash Desai M.D.
Chief Medical Officer

Ms. Jenny Hsieh
Chief Strategy Officer

Ms. Sunitha Lakshminarayanan
Sr. VP, Head of CMC & Product Devel.

Ms. Elaina Haeuber
VP & Head of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATNM Stock - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATNM shares.
View ATNM analyst ratings or view top-rated stocks.
What is Actinium Pharmaceuticals' stock price forecast for 2023?: 4 brokerages have issued 1-year price targets for Actinium Pharmaceuticals' stock. Their ATNM share price forecasts range from $11.60 to $50.00. On average, they expect the company's stock price to reach $28.32 in the next twelve months. This suggests a possible upside of 352.4% from the stock's current price.
View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts.
How have ATNM shares performed in 2023?: Actinium Pharmaceuticals' stock was trading at $10.65 on January 1st, 2023. Since then, ATNM stock has decreased by 41.2% and is now trading at $6.26.
View the best growth stocks for 2023 here.
When is Actinium Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATNM earnings forecast.
How were Actinium Pharmaceuticals' earnings last quarter?: Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08.
When did Actinium Pharmaceuticals' stock split?: Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).
What is Actinium Pharmaceuticals' stock symbol?: Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
Who are Actinium Pharmaceuticals' major shareholders?: Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.60%), Geode Capital Management LLC (2.03%), State Street Corp (1.87%), Northern Trust Corp (0.85%), Bank of New York Mellon Corp (0.45%) and Nuveen Asset Management LLC (0.39%).
View institutional ownership trends.
How do I buy shares of Actinium Pharmaceuticals?: Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Actinium Pharmaceuticals' stock price today?: One share of ATNM stock can currently be purchased for approximately $6.26.
How much money does Actinium Pharmaceuticals make?: Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $169.02 million and generates $1.03 million in revenue each year. The biotechnology company earns $-33,020,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.
How can I contact Actinium Pharmaceuticals?: Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com.

This page (NYSEAMERICAN:ATNM) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial